Opioid Withdrawal Management Market

By Drugs;

Opioid Agonists, Opioid Antagonists, Antidepressants, Anxiolytics, Anticonvulsant, and Others

By End Users;

Hospitals, Clinics, and Home Settings

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn623621704 Published Date: August, 2025

Opioid Withdrawal Management Market Overview

Opioid Withdrawal Management Market (USD Million)

Opioid Withdrawal Management Market was valued at USD 1630.61 million in the year 2024. The size of this market is expected to increase to USD 2794.57 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.0%.


Opioid Withdrawal Management Market

*Market size in USD million

CAGR 8.0 %


Study Period2025 - 2031
Base Year2024
CAGR (%)8.0 %
Market Size (2024)USD 1630.61 Million
Market Size (2031)USD 2794.57 Million
Market ConcentrationMedium
Report Pages313
1630.61
2024
2794.57
2031

Major Players

  • Alkermes Inc
  • Orexo AB
  • Ethypharm
  • Indivior PLC
  • Mylan Pharmaceuticals Inc
  • Sun Pharmaceutical Industries Inc
  • Teva Pharmaceuticals USA Inc
  • Dr. Reddys Laboratories
  • Indivior PLC
  • BioDelivery Sciences International Inc
  • Rhodes Pharmaceuticals L.P
  • Hikma Pharmaceuticals USA Inc
  • Actavis Elizabeth LLC
  • Mallinckrodt Pharmaceuticals

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Opioid Withdrawal Management Market

Fragmented - Highly competitive market without dominant players


The Opioid Withdrawal Management Market is expanding rapidly, propelled by rising opioid dependency cases. Approximately 35% of patients on long-term opioid prescriptions face addiction risks, prompting urgent attention to withdrawal solutions. As opioid misuse garners greater clinical and societal focus, structured withdrawal protocols are gaining traction across treatment landscapes.

Shift Toward Medication-Based Interventions
The growing reliance on medication-assisted treatment (MAT) is significantly reshaping how withdrawal is managed. Over 60% of withdrawal cases now incorporate medications like methadone and buprenorphine. This trend reflects a broader movement toward science-backed detox strategies that improve symptom control and reduce relapse rates.

Digital Health Solutions Enhance Accessibility
Emerging digital platforms and telehealth tools are revolutionizing how opioid withdrawal care is delivered. With around 45% of treatment setups adopting these technologies, remote therapy and adherence tracking are becoming standard. These tools not only extend care reach but also personalize withdrawal support for diverse patient populations.

Behavioral Therapies Reinforce Treatment Success
Alongside pharmacotherapy, behavioral interventions are increasingly recognized for their role in sustaining recovery. Integrated into more than 55% of treatment plans, therapies like cognitive behavioral therapy are helping address underlying psychological issues. This dual-approach ensures a more holistic recovery and reduces recurrence risks.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drugs
    2. Market Snapshot, By End Users
    3. Market Snapshot, By Region
  4. Opioid Withdrawal Management Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising opioid addiction
        2. Government initiatives support
        3. Advancements in treatment
        4. Growing awareness programs
      2. Restraints
        1. Stigma associated
        2. Limited access resources
        3. Regulatory challenges impact
        4. Cost treatment high
      3. Opportunities
        1. Expansion telemedicine services
        2. Personalized treatment plans
        3. Integration holistic approaches
        4. Development novel therapies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Opioid Withdrawal Management Market, By Drugs, 2021 - 2031 (USD Million)
      1. Opioid Agonists
      2. Opioid Antagonists
      3. Antidepressants
      4. Anxiolytics
      5. Anticonvulsant
      6. Others
    2. Opioid Withdrawal Management Market, By End Users, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Clinics
      3. Home Settings
    3. Opioid Withdrawal Management Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Alkermes Inc
      2. Orexo AB
      3. Ethypharm
      4. Indivior PLC
      5. Mylan Pharmaceuticals Inc
      6. Sun Pharmaceutical Industries Inc
      7. Teva Pharmaceuticals USA Inc
      8. Dr. Reddys Laboratories
      9. Indivior PLC
      10. BioDelivery Sciences International Inc
      11. Rhodes Pharmaceuticals L.P
      12. Hikma Pharmaceuticals USA Inc
      13. Actavis Elizabeth LLC
      14. Mallinckrodt Pharmaceuticals
  7. Analyst Views
  8. Future Outlook of the Market